EA201591454A1 - Связывающие внеклеточный матрикс синтетические пептидогликаны - Google Patents

Связывающие внеклеточный матрикс синтетические пептидогликаны

Info

Publication number
EA201591454A1
EA201591454A1 EA201591454A EA201591454A EA201591454A1 EA 201591454 A1 EA201591454 A1 EA 201591454A1 EA 201591454 A EA201591454 A EA 201591454A EA 201591454 A EA201591454 A EA 201591454A EA 201591454 A1 EA201591454 A1 EA 201591454A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding
peptidoglycany
extrawal
matrix synthetic
synthetic
Prior art date
Application number
EA201591454A
Other languages
English (en)
Russian (ru)
Inventor
Алисса Пенитч
Джон Эрик Падери
Шайли Шарма
Катерина Эллисон Стюарт
Нельда Мари Васкес-Порталатин
Original Assignee
Симик Биомедикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Симик Биомедикал, Инк. filed Critical Симик Биомедикал, Инк.
Publication of EA201591454A1 publication Critical patent/EA201591454A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Marine Sciences & Fisheries (AREA)
EA201591454A 2013-03-15 2014-03-14 Связывающие внеклеточный матрикс синтетические пептидогликаны EA201591454A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798916P 2013-03-15 2013-03-15
PCT/US2014/029596 WO2014144969A1 (en) 2013-03-15 2014-03-14 Extracellular matrix-binding synthetic peptidoglycans

Publications (1)

Publication Number Publication Date
EA201591454A1 true EA201591454A1 (ru) 2015-12-30

Family

ID=51537842

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591454A EA201591454A1 (ru) 2013-03-15 2014-03-14 Связывающие внеклеточный матрикс синтетические пептидогликаны

Country Status (14)

Country Link
US (3) US9200039B2 (enExample)
EP (1) EP2970509B1 (enExample)
JP (1) JP6603650B2 (enExample)
KR (1) KR20150130419A (enExample)
AU (1) AU2014233537A1 (enExample)
BR (1) BR112015022917A2 (enExample)
CA (1) CA2903450A1 (enExample)
EA (1) EA201591454A1 (enExample)
HK (1) HK1220217A1 (enExample)
IL (1) IL241054A0 (enExample)
MX (1) MX2015012608A (enExample)
SG (1) SG11201506966RA (enExample)
WO (1) WO2014144969A1 (enExample)
ZA (1) ZA201506391B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044239T2 (hu) 2008-03-27 2019-10-28 Purdue Research Foundation Kollagén-kötõ szintetikus peptidoglikánok, elõállításuk és alkalmazási eljárásaik
HUE031596T2 (en) 2011-05-24 2017-07-28 Symic Ip Llc Synthetic peptidoglycans that bind hyaluronic acid, their production and use
WO2014144969A1 (en) 2013-03-15 2014-09-18 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
WO2015175565A2 (en) 2014-05-12 2015-11-19 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
JP6693728B2 (ja) * 2014-11-14 2020-05-13 興和株式会社 新規な機能性ペプチド
WO2016100846A1 (en) 2014-12-19 2016-06-23 Northwestern University Thromboresistant-anticoagulant extracellular matrix
WO2016161333A2 (en) * 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
BR112017021970A2 (pt) * 2015-04-17 2018-07-10 Symic Ip Llc bioconjugados e usos dos mesmos
US10463745B2 (en) * 2015-05-12 2019-11-05 Northwestern University Materials for tissue regeneration
EP3512561A4 (en) * 2016-09-16 2020-10-07 Glycologix, LLC SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMETICS
CN111050778B (zh) 2017-07-07 2024-09-10 斯米克Ip有限公司 具有化学修饰的骨架的生物缀合物
WO2019010485A1 (en) * 2017-07-07 2019-01-10 Symic Ip, Llc TREATMENT OF FIBROSIS
AU2018298224B2 (en) 2017-07-07 2024-08-15 Symic Ip, Llc Synthetic bioconjugates
WO2019075213A1 (en) 2017-10-11 2019-04-18 Northwestern University HEPARIN CONJUGATED TO PEPTIDES BINDING TO COLLAGEN FOR TARGETING BIOLOGICAL AND SYNTHETIC FABRICS
WO2022256568A1 (en) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors
AU2023352919A1 (en) 2022-09-29 2025-03-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
JPWO2024080183A1 (enExample) * 2022-10-14 2024-04-18

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683298A (en) 1985-01-10 1987-07-28 British Columbia Research Council Process for the preparation of aminated polysaccharide derivatives
US5547936A (en) 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
FI912858A0 (fi) 1988-12-20 1991-06-13 Jolla Cancer Res Found Polypeptidpolymerkonjugat aktiva vid botande av saor.
FR2644066B1 (fr) 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
US5693625A (en) 1989-03-09 1997-12-02 Therapeutiques Substitutives Method of regenerating cells and tissues using functionalized dextrans
EP0567575B1 (en) 1991-01-14 1999-10-13 New York University Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof
JP2901787B2 (ja) 1991-07-15 1999-06-07 日本メジフィジックス株式会社 核磁気共鳴造影剤
FR2718023B1 (fr) 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
PT876165E (pt) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
CA2299687C (en) 1997-08-04 2009-10-27 Bio Syntech Ltd. Temperature-controlled ph-dependant formation of ionic polysaccharide gels
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
AU762606B2 (en) 1997-11-21 2003-06-26 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7691829B2 (en) 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
JP3103531B2 (ja) 1998-09-30 2000-10-30 延也 柳内 ヒト尿由来細胞接着糖蛋白質及びその製造方法
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20110214206A1 (en) 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
FR2794976B1 (fr) 1999-06-16 2004-05-07 Solutions Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
EP1218027B1 (en) 1999-09-15 2010-01-20 The Bruce H. DeWoolfson Irrevocable Family Trust Composition for stabilizing corneal tissue during or after orthokeratological lens wear
FR2799465B1 (fr) 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
US20030158302A1 (en) 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
EP1237585B1 (en) 1999-12-09 2003-06-18 Biosyntech Canada Inc. Mineral-polymer hybrid composition
WO2002017955A1 (en) 2000-08-30 2002-03-07 University Of Delaware Delivery system for heparin-binding growth factors
US7803905B2 (en) 2000-08-31 2010-09-28 University Of Delaware Bioactive peptide for cell adhesion
AU2002211517A1 (en) 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2002221370A1 (en) 2000-11-15 2002-05-27 Bio Syntech Canada Inc Method for restoring a damaged or degenerated intervertebral disc
US20040236092A1 (en) 2001-07-13 2004-11-25 Roman Dziarski Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof
AU2002323217B2 (en) 2001-08-15 2008-04-10 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
DE60238858D1 (de) 2001-11-15 2011-02-17 Biosyntech Canada Inc Zusammensetzung und verfahren um chitosan unter neutralen bedingungen homogen zu modifizieren oder vernetzen
US20090158452A1 (en) 2001-12-04 2009-06-18 Johnson Richard G Transgenic plants with enhanced agronomic traits
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2003075848A2 (en) 2002-03-08 2003-09-18 Zymogenetics, Inc. Inhibitors for use in hemostasis
US7666852B2 (en) 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
JP2005185101A (ja) 2002-05-30 2005-07-14 National Institute Of Agrobiological Sciences 植物の全長ｃＤＮＡおよびその利用
US8673333B2 (en) 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
US7862831B2 (en) 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US20090183270A1 (en) 2002-10-02 2009-07-16 Adams Thomas R Transgenic plants with enhanced agronomic traits
JP2006501846A (ja) 2002-10-04 2006-01-19 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ローソニア・イントラセルラリス由来の核酸およびポリペプチド配列ならびに使用方法
US20050069572A1 (en) 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
FR2846659B1 (fr) 2002-10-30 2005-02-18 Centre Nat Rech Scient Fragments peptidiques du facteur harp inhibant l'angiogenese
WO2004045542A2 (en) 2002-11-15 2004-06-03 Arizona Board Of Regents Arizona State University Therapeutic bioconjugates
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
PL1677807T3 (pl) 2003-10-28 2011-05-31 Organes Tissus Regeneration Reparation Remplacement Otr3 Zastosowanie polimerów bio-kompatybilnych do wytwarzania kompozycji lub wyrobu medycznego
FR2861308A1 (fr) 2003-10-28 2005-04-29 Organes Tissus Regeneration Re Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs
WO2005055800A2 (en) 2003-12-15 2005-06-23 Technion Research & Development Foundation Ltd. Therapeutic drug-eluting endoluminal covering
EP2289567A3 (en) 2003-12-22 2011-06-22 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US7709439B2 (en) 2004-02-20 2010-05-04 Boston Scientific Scimed, Inc. Biomaterials for enhanced healing
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
EP1758931A1 (en) 2004-05-31 2007-03-07 National University of Singapore Peptides derived from decorin leucine rich repeats and uses thereof
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
WO2006036681A2 (en) 2004-09-22 2006-04-06 Cartilix, Inc. Cartilage filling device
EP1804844A4 (en) 2004-09-29 2012-02-29 Univ Singapore COMPOSITE, PROCESS FOR ITS MANUFACTURE AND ITS APPLICATIONS
US20060241022A1 (en) 2004-10-06 2006-10-26 Bowen Benjamin P Selectin targeting bioconjugates
WO2006047758A1 (en) 2004-10-27 2006-05-04 Massachusetts Institute Of Technology Novel technique to fabricate molded structures having a patterned porosity
WO2007044026A2 (en) 2004-11-23 2007-04-19 The Johns Hopkins University Compositions comprising modified collagen and uses therefore
WO2006089167A1 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Glucosamine materials
WO2006089119A2 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
CA2598251A1 (en) 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
GB2424223C (en) 2005-03-07 2011-02-02 Massachusetts Inst Technology Biomaterial.
EP1863404A2 (en) 2005-03-30 2007-12-12 Cartilix, Inc. Coated medical device
US8415325B2 (en) 2005-03-31 2013-04-09 University Of Delaware Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels
US7737131B2 (en) 2005-03-31 2010-06-15 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8338390B2 (en) 2005-03-31 2012-12-25 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8367639B2 (en) 2005-03-31 2013-02-05 University Of Delaware Hydrogels with covalent and noncovalent crosslinks
EP1882392A4 (en) 2005-05-10 2009-07-01 Monsanto Technology Llc GENES AND THEIR USES FOR PLANT IMPROVEMENTS
JP5140579B2 (ja) 2005-06-08 2013-02-06 カンジェーン コーポレイション 病原菌に対する生体防御を増強するヒアルロン酸結合性ペプチド
US20080069774A1 (en) 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
JP2009529374A (ja) 2006-03-07 2009-08-20 アクスル インターナショナル 治療及び癒着防止用生物活性スキャホールド
US20070212385A1 (en) 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
JP2009529967A (ja) 2006-03-15 2009-08-27 サーモディクス，インコーポレイティド 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用
WO2008034648A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20090162436A1 (en) 2006-06-14 2009-06-25 Carson Daniel D Compositions and methods for repair of tissues
WO2010033564A1 (en) 2008-09-17 2010-03-25 Ceres, Inc. Transgenic plants having increased biomass
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US8114835B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles for tissue engineering
US8114834B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles
US20100222546A1 (en) 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
US8188220B2 (en) 2006-12-06 2012-05-29 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting wounds, regenerating tissue, and tumors
WO2008070179A2 (en) 2006-12-06 2008-06-12 Monsanto Technology, Llc Genes and uses for plant improvement
PL2497505T3 (pl) 2007-04-16 2017-02-28 Regentis Biomaterials Ltd. Kompozycje i sposoby tworzenia rusztowania
US20100119577A1 (en) 2007-05-06 2010-05-13 Byoung-Hyun Min Therapeutic composite for cartilage disorder using extracellular matrix (ecm) scaffold
US20100191215A1 (en) 2007-06-12 2010-07-29 By-Pass ,Inc. Pressure pulse actuating device for delivery systems
US20090075281A1 (en) 2007-07-10 2009-03-19 Regents Of The University Of California Mtbe genes
US7993679B2 (en) 2007-09-25 2011-08-09 Integra Lifesciences Corporation Flowable wound matrix and its preparation and use
US20100210509A1 (en) 2007-10-09 2010-08-19 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
WO2009099580A2 (en) 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
HUE044239T2 (hu) * 2008-03-27 2019-10-28 Purdue Research Foundation Kollagén-kötõ szintetikus peptidoglikánok, elõállításuk és alkalmazási eljárásaik
CN102177180A (zh) 2008-04-04 2011-09-07 犹他州大学研究基金会 烷基化半合成的糖胺聚糖醚及其制备和使用方法
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
US20100004196A1 (en) 2008-06-17 2010-01-07 Hopitaux Universitaires De Geneve Heparan sulfate proteoglycan composition and use thereof
WO2010011857A2 (en) 2008-07-23 2010-01-28 The Johns Hopkins University Parenteral administration of a glucosamine
US20110269208A1 (en) 2008-08-15 2011-11-03 The Trustees Of The University Of Pennsylvania Cross-linked polymer network formed by sequential cross-linking
FR2936247B1 (fr) 2008-09-24 2010-10-22 Ct Hospitalier Universitaire De Dijon Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire.
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
EP2358758B1 (de) 2008-11-28 2012-09-05 Zetascience GmbH Bioaktives hydrogel
KR101062068B1 (ko) 2008-12-01 2011-09-02 포항공과대학교 산학협력단 유착방지용 조성물
IL195764A0 (en) 2008-12-07 2009-11-18 Technion Res & Dev Foundation Compositions and methods for drug delivery
WO2010083179A2 (en) 2009-01-16 2010-07-22 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soybeans and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
BRPI1013179A2 (pt) 2009-03-30 2019-09-24 Prometheus Laboratories Inc peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado
WO2010115156A2 (en) 2009-04-03 2010-10-07 Synthetic Genomics, Inc. Endophytic fungus and uses therefor
AU2010236584A1 (en) 2009-04-13 2011-11-10 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
FI20095452A0 (fi) 2009-04-23 2009-04-23 Suomen Punainen Risti Veripalv Uudet haaraiset sokerianalyysit
US20120100106A1 (en) 2009-05-04 2012-04-26 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
EP2499167A4 (en) 2009-11-09 2013-07-10 Univ Drexel COMPOSITIONS AND METHODS FOR TREATING AN ILLNESS OR MALFUNCTION IN SOFT TISSUE
EA201290442A1 (ru) 2009-12-04 2012-11-30 Юклид Системз Корпорэйшн Композиция и способы профилактики и лечения макулярной дегенерации, диабетической ретинопатии и диабетического макулярного отека
US8846020B2 (en) 2009-12-16 2014-09-30 Regentis Biomaterials Ltd. Scaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof
WO2011094149A1 (en) 2010-01-26 2011-08-04 University Of Utah Research Foundation Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
EP3569241A1 (en) 2010-02-26 2019-11-20 Vascular Biosciences, Inc. Car peptide for homing, diagnosis & targeted therapy for pulmonary and fibrotic disorders
ES2742218T3 (es) 2010-06-23 2020-02-13 Purdue Research Foundation Peptidoglicanos sintéticos que se enlazan al colágeno destinados a ser utilizados en operaciones vasculares
US9173919B2 (en) 2011-02-16 2015-11-03 Purdue Research Foundation Collagen-targeted nanoparticles
WO2012149515A2 (en) 2011-04-29 2012-11-01 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
HUE031596T2 (en) 2011-05-24 2017-07-28 Symic Ip Llc Synthetic peptidoglycans that bind hyaluronic acid, their production and use
WO2013110056A1 (en) 2012-01-19 2013-07-25 The Johns Hopkins University Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
US9540428B2 (en) 2012-07-03 2017-01-10 Ecole Polytechnique Federale De Lausanne (Epfl) Extracellular matrix heparin-binding domains
WO2014028209A1 (en) 2012-08-14 2014-02-20 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
WO2014038866A1 (ko) 2012-09-05 2014-03-13 아주대학교산학협력단 연골세포 유래 세포외 기질막을 이용한 신생혈관질환 치료용 조성물 및 각막 또는 결막 이식재
DE102012108560B4 (de) 2012-09-13 2018-12-20 Leibniz-Institut Für Polymerforschung Dresden E.V. Nichtkovalente selbstorganisierende Hydrogelmatrix für biotechnologische Anwendungen
CN104870020A (zh) 2012-10-19 2015-08-26 康奈尔大学 用于关节软骨的仿生型界面润滑剂
EP2915001A4 (en) 2012-11-01 2016-05-04 Univ Johns Hopkins CONTACT LENS SURFACE MODIFICATION WITH A HYALURONIC ACID BINDING PEPTIDE FOR THE ACCUMULATION AND STORAGE OF HYALURONIC ACID
US20140186350A1 (en) 2012-12-18 2014-07-03 Novartis Ag Compositions and methods for long acting molecules
WO2014144969A1 (en) 2013-03-15 2014-09-18 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
WO2014171084A1 (ja) 2013-04-16 2014-10-23 パナソニックＩｐマネジメント株式会社 電力変換装置、電力変換方法、モータシステム、３相モータ
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
WO2015175565A2 (en) 2014-05-12 2015-11-19 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
WO2016061145A1 (en) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
US20170368192A1 (en) 2014-10-13 2017-12-28 Symic Ip, Llc Luminal vessel coating for arteriovenous fistula
WO2016065083A1 (en) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
WO2016161333A2 (en) 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
BR112017021970A2 (pt) 2015-04-17 2018-07-10 Symic Ip Llc bioconjugados e usos dos mesmos
US20170112941A1 (en) 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate

Also Published As

Publication number Publication date
CA2903450A1 (en) 2014-09-18
KR20150130419A (ko) 2015-11-23
WO2014144969A1 (en) 2014-09-18
ZA201506391B (en) 2017-09-27
EP2970509B1 (en) 2020-05-13
HK1220217A1 (zh) 2017-04-28
AU2014233537A1 (en) 2015-09-10
US20190022175A1 (en) 2019-01-24
US20140288002A1 (en) 2014-09-25
US9872887B2 (en) 2018-01-23
JP2016516065A (ja) 2016-06-02
US20160129076A1 (en) 2016-05-12
IL241054A0 (en) 2015-11-30
MX2015012608A (es) 2016-07-06
SG11201506966RA (en) 2015-10-29
US9200039B2 (en) 2015-12-01
EP2970509A4 (en) 2016-11-02
EP2970509A1 (en) 2016-01-20
BR112015022917A2 (pt) 2017-07-18
JP6603650B2 (ja) 2019-11-06

Similar Documents

Publication Publication Date Title
EA201591454A1 (ru) Связывающие внеклеточный матрикс синтетические пептидогликаны
UY4236Q (es) Configuración aplicada en zapato
UY34885A (es) Proteínas de unión anti-mesotelina
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
MX391989B (es) Conjugados de amatoxina y anticuerpos.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
BR112014030278A2 (pt) anticorpo, e, composição.
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
MX373334B (es) Composiciones y métodos.
JO3567B1 (ar) جزيئات جسم مضاد لـ tim-3 واستخداماتها
SG10201811017QA (en) Novel antibody frameworks
UY35483A (es) Anticuerpos pac1 humanos
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
SI2976084T1 (sl) Kombinacija, ki vsebuje zidovudin in prolimiksin
UY4223Q (es) Banco
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
SE542188C2 (en) Supports for membrane enhanced peptide synthesis
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
UY4233Q (es) Configuración aplicada en zapato
UY4243Q (es) Banco
UA116372C2 (uk) Частинки резинату фенілефрину